Pulse Biosciences Company Profile (NASDAQ:PLSE)

About Pulse Biosciences (NASDAQ:PLSE)

Pulse Biosciences logoPulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret's esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PLSE
  • CUSIP: N/A
  • Web: www.pulsebiosciences.com
Capitalization:
  • Market Cap: $337.85 million
  • Outstanding Shares: 14,334,000
Average Prices:
  • 50 Day Moving Avg: $18.62
  • 200 Day Moving Avg: $24.70
  • 52 Week Range: $5.20 - $39.50
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.69 per share
  • Price / Book: 13.94
Profitability:
  • EBITDA: ($14,340,000.00)
  • Return on Equity: -57.16%
  • Return on Assets: -53.58%
Debt:
  • Current Ratio: 8.18%
  • Quick Ratio: 8.18%
Misc:
  • Average Volume: 297,117 shs.
  • Beta: 3.24
  • Short Ratio: 7.67
 

Frequently Asked Questions for Pulse Biosciences (NASDAQ:PLSE)

What is Pulse Biosciences' stock symbol?

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences, Inc (NASDAQ:PLSE) announced its quarterly earnings data on Thursday, July, 27th. The company reported ($0.43) EPS for the quarter. View Pulse Biosciences' Earnings History.

When will Pulse Biosciences make its next earnings announcement?

Pulse Biosciences is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Pulse Biosciences.

Who are some of Pulse Biosciences' key competitors?

When did Pulse Biosciences IPO?

(PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.

Who owns Pulse Biosciences stock?

Pulse Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include DUGGAN ROBERT W (35.70%), DUGGAN ROBERT W (26.70%) and DUGGAN ROBERT W (23.90%). Company insiders that own Pulse Biosciences stock include Maky Zanganeh, Mitchell E Levinson, Robert J Greenberg, Robert W Duggan and Thierry B Thaure. View Institutional Ownership Trends for Pulse Biosciences.

How do I buy Pulse Biosciences stock?

Shares of Pulse Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pulse Biosciences' stock price today?

One share of Pulse Biosciences stock can currently be purchased for approximately $23.56.


MarketBeat Community Rating for Pulse Biosciences (NASDAQ PLSE)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  46 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  90
MarketBeat's community ratings are surveys of what our community members think about Pulse Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pulse Biosciences (NASDAQ:PLSE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Pulse Biosciences (NASDAQ:PLSE)
Price Target History for Pulse Biosciences (NASDAQ:PLSE)
Analysts' Ratings History for Pulse Biosciences (NASDAQ:PLSE)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Pulse Biosciences (NASDAQ:PLSE)
Earnings by Quarter for Pulse Biosciences (NASDAQ:PLSE)
Earnings History by Quarter for Pulse Biosciences (NASDAQ PLSE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017N/AView Earnings Details
7/27/2017Q2 2017($0.43)ViewN/AView Earnings Details
5/4/2017Q2 2017($0.23)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pulse Biosciences (NASDAQ:PLSE)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Pulse Biosciences (NASDAQ:PLSE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Pulse Biosciences (NASDAQ:PLSE)
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 9.55%
Insider Trades by Quarter for Pulse Biosciences (NASDAQ:PLSE)
Institutional Ownership by Quarter for Pulse Biosciences (NASDAQ:PLSE)
Insider Trades by Quarter for Pulse Biosciences (NASDAQ:PLSE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/24/2017Robert W DugganMajor ShareholderBuy2,000,000$15.02$30,040,000.00View SEC Filing  
9/18/2017Maky ZanganehDirectorBuy29,775$13.36$397,794.00View SEC Filing  
9/18/2017Robert W DugganMajor ShareholderBuy409,918$14.36$5,886,422.48View SEC Filing  
9/14/2017Mitchell E LevinsonDirectorBuy3,835$12.30$47,170.50View SEC Filing  
8/3/2017Maky ZanganehDirectorBuy28,790$23.96$689,808.40View SEC Filing  
8/3/2017Robert W DugganMajor ShareholderBuy277,450$23.14$6,420,193.00View SEC Filing  
8/2/2017Maky ZanganehDirectorBuy8,290$25.15$208,493.50View SEC Filing  
5/23/2017Robert W DugganMajor ShareholderBuy83,928$26.86$2,254,306.08View SEC Filing  
5/22/2017Robert W DugganMajor ShareholderBuy34,728$26.25$911,610.00View SEC Filing  
5/12/2017Thierry B ThaureDirectorSell10,000$24.40$244,000.00View SEC Filing  
5/11/2017Robert W DugganMajor ShareholderBuy43,389$21.04$912,904.56View SEC Filing  
5/10/2017Robert J GreenbergDirectorSell25,000$21.12$528,000.00View SEC Filing  
5/8/2017Thierry B ThaureDirectorSell15,000$22.49$337,350.00View SEC Filing  
4/28/2017Robert W DugganMajor ShareholderBuy84,348$23.88$2,014,230.24View SEC Filing  
4/27/2017Robert W DugganMajor ShareholderBuy35,387$24.79$877,243.73View SEC Filing  
4/19/2017Robert W DugganMajor ShareholderBuy150,123$23.77$3,568,423.71View SEC Filing  
4/18/2017Robert W DugganMajor ShareholderBuy61,819$25.49$1,575,766.31View SEC Filing  
4/17/2017Robert W DugganMajor ShareholderBuy107,300$24.81$2,662,113.00View SEC Filing  
4/10/2017Robert W. DugganMajor ShareholderBuy191,464$19.75$3,781,414.00View SEC Filing  
3/20/2017Maky ZanganehDirectorBuy18,240$23.34$425,721.60View SEC Filing  
3/18/2017Robert W DugganMajor ShareholderBuy205,127$23.56$4,832,792.12View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Pulse Biosciences (NASDAQ:PLSE)
Latest Headlines for Pulse Biosciences (NASDAQ:PLSE)
Source:
Loading headlines, please wait.

Social

Chart

Pulse Biosciences (PLSE) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.